Product Image
Please see full prescribing and safety information, including boxed warning, for BACLOFEN 10 mg per 20 mL and 40 mg per 20 mL vials, 20,000 mcg per 20 mL vials   and 0.05 mg per 1 mL syringes.

Available in:

  • 10 mg per 20 mL single-dose vials
  • 40 mg per 20 mL single-dose vials
  • 20,000 mcg per 20 mL single-dose vials
  • 0.05 mg per mL prefilled syringes
  • A pump refill convenience kit is available with all vial orders


  • AP Rated
  • Preservative-free
  • Not made with natural rubber latex

BACLOFEN Injection, USP and BACLOFEN Injection (Intrathecal), USP*

Brand Name Equivalent: GABLOFEN® (GABLOFEN is a registered trademark of Piramal Critical Care Inc.)
Therapeutic Category: Muscle Relaxant

PreventIV Measures® Features:

  • Easy-to-read drug name and dosage strength to aid in identifying the right product
  • Bar codes included on the vial, syringe and carton for ease of scanning
  • Unique label design to help products stand out on the shelf
  • Enhanced packaging and labeling designed to promote safety and help reduce the risk of medication errors
Description Strength Fill
Concentration Container
Closure Unit
of Sale
678-20 Glass Vial* 10 mg 20 mL 500 mcg per mL 20 mL 20 mm 1
679-20 Glass Vial* 40 mg 20 mL 2,000 mcg per mL 20 mL 20 mm 1
680-20 Glass Vial* 20,000 mcg 20 mL 1,000 mcg per mL 20 mL 20 mm 1
681-71 Prefilled Syringe 0.05 mg 1 mL 50 mcg per mL N/A N/A 2
Item Number Description Unit
of Sale
032502190001 Pump Refill Convenience Kit 1
*A pump refill convenience kit is available
Abrupt discontinuation of intrathecal baclofen, regardless of the cause, has resulted in sequelae that include high fever, altered mental status, exaggerated rebound spasticity, and muscle rigidity, that in rare cases has advanced to rhabdomyolysis, multiple organ-system failure and death. Prevention of abrupt discontinuation of intrathecal baclofen requires careful attention to programming and monitoring of the infusion system, refill scheduling and procedures, and pump alarms. Patients and caregivers should be advised of the importance of keeping scheduled refill visits and should be educated on the early symptoms of baclofen withdrawal. Special attention should be given to patients at apparent risk (e.g. spinal cord injuries at T-6 or above, communication difficulties, history of withdrawal symptoms from oral or intrathecal baclofen). Consult the technical manual of the implantable infusion system for additional postimplant clinician and patient information (see WARNINGS).